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CORRESPONDENCE

COVID-19
Presenting as
Acute Hepatitis
Praneet Wander, MD1, Marcia Epstein, MD2 and
David Bernstein, MD1
Am J Gastroenterol 2020;00:1–2. https://doi.org/
10.14309/ajg.0000000000000660

Coronavirus disease (COVID-19) is
a novel enveloped RNA betacoronavirus
that emerged from Wuhan, China, in
December 2019 and rapidly has become
a worldwide pandemic aﬀecting hundreds
of thousands of people and causing death
in an estimated 0.5%–3% of infected cases
(1). The most common clinical presentation is respiratory symptoms such as
fever, shortness of breath, and cough associated with radiographical ﬁndings
consistent with pneumonia (2). The
prevalence of abnormal liver tests on the
initial presentation of COVID-19 is still
undetermined. Currently, there are no
approved therapies for COVID-19 other
than supportive care, enrollment in clinical trials, and the use of oﬀ-label therapies
such as vitamin C and hydroxychloroquine without supportive, randomized clinical trials to support their
eﬃcacy. We report our ﬁrst case of
COVID-19 presenting as acute, nonicteric
hepatitis.
A 59-year-old woman presented to the
emergency department with a chief concern of dark urine. On entering our facility, she was isolated and a surgical mask
was placed on her face as per our protocol.
She denied cough, sore throat, shortness of
breath, diarrhea, nausea, vomiting, or abdominal pain. She lives alone and denied
sick contacts. She had a medical history of
well-controlled human immunodeﬁciency virus (CD4 499 and viral load undetectable), hypertension, hyperlipidemia,
Graves disease, and a left facial paralysis
secondary to previous actinomycosis infection. She denied recent intake of
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acetaminophen or any antibiotics. Her
outpatient medications included clonidine, ﬁsh oil, levothyroxine, amlodipine,
propranolol, hydrochlorothiazide, MVI,
and Genvoya (elvitegravir, cobicistat,
emtricitabine, and tenofovir alafenamide).
Recent outpatient liver chemistries were
normal. She was admitted because of the
concern of rising liver tests in a patient
with human immunodeﬁciency virus
disease.
On presentation, her temperature was
37.2 °C. There were no cutaneous manifestations, her lung examination was
normal, and there was no jaundice, right
upper quadrant tenderness, hepatomegaly, or splenomegaly. Laboratory results
were as follows: white blood cell count 3.71
G/L, platelets 140 G/L, serum bilirubin 0.6
mg/dL (N: , 25), AST 1230 IU/L (N: ,
50), ALT 697 IU/L (N: , 50), alkaline
phosphatase 141 IU/L (N: , 125), serum
albumin 3.1 g/dL (N: . 3.5), INR 1.08, and
ferritin 6,606 ng/mL (N: ,150). An abdominal sonogram with Doppler revealed
a normal liver with patent vasculature.
The following serological tests were performed and all tested negative: hepatitis A,
B, C, E, Cytomegalovirus, Epstein-Barr
and respiratory viral panel. Blood cultures
and screening for autoimmune markers
were negative.
On admission day 2, 18 hours after
presentation to the emergency department, she developed a fever to 39 °C
with SpO2 94% on room air. A chest x-ray
showed bilateral interstitial opacities. Nasopharyngeal samples taken for the SARSCoV PCR test were positive, and the patient was placed on 3 L of oxygen. On
admission day 4, she was started on a 5day course of hydroxychloroquine 200 mg
BID. She did well and was discharged to
home on hospital day 8 with serum bilirubin 0.6 mg/dL, AST 114 IU/L, ALT 227
IU/L, alkaline phosphatase 259 IU/L, serum albumin 2.8 g/dL, and INR 1.13
(Figure 1). Her outpatient medications
including her human immunodeﬁciency
virus treatment were continued throughout her entire admission.
COVID-19 infection typically presents
with respiratory symptoms such as fever,
sore throat, cough, and shortness of
breath. In high-volume centers such as

ours, liver test abnormalities are being
noted following COVID-19 diagnosis. We
report our ﬁrst case of COVID-19 infection presenting as acute nonicteric
hepatitis before the development of fever
and respiratory symptoms.
Our patient was on a stable outpatient
medication regimen and had normal
outpatient liver tests just before admission
for COVID-19. Her initial presentation
was not typical for COVID-19, and she
was evaluated for acute hepatitis. This
workup was negative, and 18 hours after
admission, she developed respiratory
symptoms and was subsequently diagnosed with COVID-19. She was treated
for COVID-19 with hydroxychloroquine,
and her symptoms improved, as did her
liver chemistries. Because all other causes
of acute nonicteric hepatitis were ruled
out, it seems highly likely that her acute
hepatitis was caused by COVID-19
infection.
There is currently no standard of care
for the treatment of COVID-19 infection.
Current therapies include implementing
infection control measures, symptomatic
treatment, and supportive care including
supplemental oxygen and mechanical
ventilation when appropriate. There are
currently no approved therapies to treat
COVID-19 infection. Clinical trials are
ongoing to evaluate antiviral therapies and
immune-modulator therapies.
The
antimalarial
and
antiinﬂammatory medication, hydroxychloroquine, has been widely used to treat
COVID-19 infection without any available data from randomized clinical trials
to inform clinical guidance on the use,
dosing, or duration of hydroxychloroquine for prophylaxis or the treatment of COVID-19 infection (3).
Hydroxychloroquine has been shown to
have in vitro activity against SARS-CoV
and SARS-CoV-2 (COVID-19) (4). A single, nonrandomized study of 36 patients in
France suggested that hydroxychloroquine
lowered coronavirus levels in the blood as
compared to untreated controls and
shortened recovery time (5). Six of the 20
patients who received hydroxychloroquine
also received azithromycin, whereas none
of the control received azithromycin. A
randomized study from China reported
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Figure 1. Liver tests during hospital course.

that hydroxychloroquine showed no beneﬁt in treating COVID-19 infection (6).
Hydroxychloroquine is currently under
investigation in clinical trials for preexposure or postexposure prophylaxis of
COVID-19 infection and treatment of
patients with mild, moderate, and severe
COVID-19.
On review of the limited literature to
date, our case appears to be the ﬁrst
reported case of COVID-19 infection
presenting as acute hepatitis before the
development of respiratory symptoms.
Clinicals should be aware in this era of
COVID-19 infection that acute nonicteric
hepatitis may be the virus’ initial

The American Journal of GASTROENTEROLOGY

presentation before the development of
respiratory symptoms. Patients with risk
factors for COVID-19 presenting with
acute hepatitis should be isolated and
undergo testing for COVID-19. Further
observational studies are needed to determine the frequency of this presentation
and that of mild-to-moderate liver test
abnormalities during this evolving
pandemic.
CONFLICTS OF INTEREST

Guarantor of the article: David
Bernstein, MD.
Speciﬁc author contributions: All authors
contributed to the writing of the case report.

1. Chen N, Zhou M, Dong X, et al.
Epidemiological and clinical characteristics of
99 cases of 2019 novel coronavirus pneumonia
in Wuhan, China: A descriptive study. Lancet
2020;395:507–13.
2. Huang C, Wang Y, Li X, et al. Clinical features
of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet 2020;
395:497–506.
3. CDC.gov. Accessed March 29, 2020.
4. Yao X, Ye F, Zhang M, et al. In vitro antiviral
activity and projection of optimized dosing design
of hydroxychloroquine for the treatment of severe
acute respiratory syndrome coronavirus 2 (SARSCoV-2). Clin Infect Dis 2020:ciaa237. doi: 10.
1093/cid/ciaa237. [Epub ahead of print].
5. Gautret P, Lagier JC, Parola P et al.
Hydroxychloroquine and azithromycin as
a treatment of COVID-19: Results of an openlabel non-randomized clinical trial. Int J
Antimicrob Agents 2020. Accessed March 29,
2020. [Epub ahead of print].
6. Chen J, Liu D, Liu L, et al. A pilot study of
hydroxychloroquine in treatment of patients
with common coronavirus-19. J Zhejiang Univ
2020. Accessed March 29, 2020. doi: 10.3785/j.
issn.1008-9292.2020.03.03.
1
Division of Hepatology, Northwell Health and
Zucker School of Medicine at Hofstra/Northwell,
Hempstead, New York, USA; 2Division of
Infectious Diseases, Northwell Health and Zucker
School of Medicine at Hofstra/Northwell,
Hempstead, New York, USA. Correspondence:
Praneet Wander, MD. E-mail: praneet_wander@
hotmail.com.

VOLUME 00 | MONTH 2020 www.amjgastro.com

Copyright © 2020 by The American College of Gastroenterology. Unauthorized reproduction of this article is prohibited.

